Chris Adams

Chris Adams is an accomplished professional in the field of proteomics and mass spectrometry, currently serving as the Director of Proteomics at Rezo Therapeutics since April 2023. Prior experience includes roles as Director of Business Development and West Coast Proteomics Manager at Bruker Daltonics from March 2018 to April 2023, and Director of Proteomics at Stanford University from September 2007 to March 2018. Chris began a research career as a PhD student at Uppsala University from 2003 to 2007 and held research associate positions at Amgen and Baxter Biosciences early in the career. Chris holds a Doctor of Philosophy (PhD) in Biological and Medical Mass Spectrometry from Uppsala University and a Bachelor of Science (BSc) in Biochemistry from California Polytechnic State University-San Luis Obispo.